Adipose-derived regenerative cell therapy inhibits the progression of monocrotaline-induced pulmonary hypertension in rats

Abstract

The development of PH was inhibited by ADRCs through suppressing changes in the expression of genes associated with ET and TGF-β systems. We believe that ADRC therapy could serve as a novel strategy for treating PH.

Preventive aerobic training exerts a cardioprotective effect on rats treated with monocrotaline

“…Soon physical training improved RV function without changing the PAH severity, which can be justified by some direct actions of the training in the RV, without decreasing the PAH, mechanisms have not been studied but have been elucidated in previous studies (Ryan & Archer 2014;Talati & Hemnes 2015). Other studies using this model evaluated cardiac function through catheterization (Colombo et al 2013); however, echocardiography also evaluates cardiac function and is not an invasive method (Alencar et al 2014;Eguchi et al 2014).…”

“…; Eguchi et al . ). Pulmonary velocity acceleration time is an indicator of the severity of pulmonary hypertension, and the higher the level of systolic pulmonary artery pressure, the smaller the value of PVAT.…”

“…Rats were anesthetized by intraperitoneal injection of ketamine (50 mg/kg) and xylazine (0.5 mg/kg). Pulmonary artery flow was obtained by pulsed Doppler, and the time to peak flow velocity [pulmonary velocity acceleration time (PVAT)], pulmonary ejection time (PET) and peak flow velocity (PFV) were measured (Martinez et al 2011;Eguchi et al 2014). Pulmonary velocity acceleration time is an indicator of the severity of pulmonary hypertension, and the higher the level of systolic pulmonary artery pressure, the smaller the value of PVAT.…”

Therapeutic potential of adipose stem cell‐derived conditioned medium against pulmonary hypertension and lung fibrosis

“…Although there have been recent reports demonstrating beneficial effects of adipose stem cell therapy in models of PH and PF (Eguchi et al , ; Lee et al, ; Somanna et al , ; Luo et al , ), this is the first report to demonstrate that the secretions of ASCs also result in similar therapeutic effects in these diseases. This concept that secretions from stem cells may be responsible for the observed beneficial effects of stem cell therapy is now a prevalent theory (Blaber et al , ; Sabin and Kikyo, ).…”

“…Moreover, comparison of BM‐MSCs and ASCs indicate that the latter may offer enhanced therapeutic benefits for treating certain pathological conditions (Ikegame et al , ; Paul et al , ). Recent reports have shown that cultured mesenchymal or stromal cells isolated from adipose tissue attenuate MCT‐induced PH (Eguchi et al , ; Somanna et al , ; Luo et al , ). Likewise, numerous preclinical studies have been conducted using various cell‐types including alveolar epithelial type II cells (AECs), BM‐MSCs and induced pluripotent stem cells (iPSCs) to treat Bleo‐induced PF (McNulty and Janes, ).…”